Navigation Links
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
Date:6/17/2008

contains statements that are forward looking, including statements related to future clinical development plans for PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a resul
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... which brings Q3 orders to $5.8 million and provides a good ... in North America and one in the ... bid new projects at record levels," said Peter Bruijns , ... at the end of Q3 than they have been for any ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Health, Labor and Welfare (MHLW), for the revolutionary medical ... ... blood, IRVINE, Calif., Nov. 27 Masimo, the inventor,of ... announced approval of the Masimo Rad-57 Pulse CO-Oximeter,bringing the world,s ...
... Research &,Instrumentation, Inc. (CRi) announces the launch of ... Maestro 2 received widespread acclaim,at the both the ... conference for in vivo imaging, and at the ... 2, the fully,automated version of the award-winning Maestro ...
... 26 Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... announced that Dr. Leslie J. Browne,President and Chief Executive ... Focus on Healthcare Conference hosted by,BMO Capital Markets. The ... Broadway Hotel in New York City., Dr. Browne,s ...
Cached Biology Technology:Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4CRi Announces Maestro 2, the Next Generation in Vivo Optical Imaging Systems 2Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 2Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 3
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... biophysics textbook and it describes how life functions and ... into biological systems and provides an understanding of the ... how our genes make proteins that control the dynamics ... an organism. It quantifies the principles of life and ... on both large and small scales. The book is ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... PA, October 28, 2008 A growing body of ... from grapes, including red wine, helps reduce the risk ... the November issue of Nutrition Research . ... such as red wine may be beneficial in preventing ...
... However, how the step from gene to anti-bacterial effect occurs ... B. Pseudomallei, a bacterium suitable for bioweapons, had managed ... body for many years without being detected by the immune ... the body, resulting in the patient dying from blood poisoning. ...
... event organised by the trinational Transalpine Biocluster ... will bring together researchers and professionals from academia ... the most recent findings in the fields of ... new and exciting developments in the technology and ...
Cached Biology News:Mounting evidence shows health benefits of grape polyphenols 2Bridging public and private research on bioinformatics and proteomics 2
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
... for 25 chips provides the chips and ... (at picogram levels) with the Experion automated ... HighSens microfluidic chips, 2 x 1,250 microliters ... HighSens stain, 20 microliters RNA ladder, 2 ...
Biology Products: